Ингибитор ВИЧ протеазы ASC09F
Международное непатентованное наименование
Ингибитор ВИЧ протеазы ASC09F
Торговое наименование
-
Производитель, страна
Ascletis Pharmaceuticals Co., China
Лекарственная форма
tablet, 400mg
Механизм действия
Protease inhibitor (PI). Is a novel HIV-1 PI that is structurally similar to the FDA-approved PI darunavir (Prezista). PIs bind the HIV-1 protease enzyme to inhibit cleavage of viral Gag and Gag-Pol polyproteins, thereby preventing the formation of mature, infectious virus particles. ASC09F is characterized as having a broader in vitro resistance profile than that of currently approved PIs, including darunavir.
Клинические исследования
1.
Название протокола
A Randomized, Open-label, Multi-centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Pneumonia Caused by Novel Coronavirus Infection
Дата начала и окончания КИ
February 7, 2020 - June 30, 2020
Название организации, проводящей КИ
First Affiliated Hospital of Zhejiang University
Страны
China
Фаза
-
Кол-во пациентов
160
2.
Название протокола
A Randomized,Open,Controlled Small Sample Clinical Study to Evaluate the Efficacy and Safety of ASC09/Ritonavir Compound Tablets and Ritonavir for 2019-nCoV Pneumonia
Дата начала и окончания КИ
February 1, 2020 - July 1, 2020
Название организации, проводящей КИ
Tongji Hospital
Страны
China
Фаза
III
Кол-во пациентов
60